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Conclusions: Dose delivery in breast cancer patients irradiated during 
vmDIBH, as verified in vivo with 2D EPID dosimetry, is as accurate as 
in patients irradiated during FB. 
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Purpose/Objective: The aim of this study was to find out early 
cardiac changes from doxorubicin based chemotherapy and 
radiotherapy in patients with early and locally advanced carcinoma 
breast and to assess cardiac changes in relation to radiation dose 
received by heart. 
Materials and Methods: Investigations like ECG, ECHO and ERV 
(Equilibrium radionuclide ventriculography) were done at baseline, 
after chemotherapy, after radiotherapy and after 6 months of 
followup. Changes in ECG, ECHO and ERV were recorded at different 
time periods during the study. Left ventricular ejection fraction 
(LVEF) was recorded using both ECHO and ERV. In ECHO other 
parameters like Fractional shortening (FS), Mitralvalve E point septal 
separation (MVEPSS) and PEP/LVET ratio (Pre ejectionperiod/Left 
ventricular ejection time) were recorded. Patients were divided into 4 
groups according to the sequence of chemotherapy and radiotherapy. 
Results: The most common ECG change was T wave inversion in the 
pre-cordial leads. One patient had ST depression in V4 & V5 leads and 
2 patients had physiological T wave inversion in Lead III. In Group 1 
mean LVEF (ECHO) at baseline was 66.79 ±3.73. It decreased to 63.45 
± 3.54 after chemotherapy. It further decreased to 61.64 ± 4.26 after 
RT. On follow up there was a further decline to 61.42 ±3.27. In Group 
2 baseline mean LVEF was 66.67 ± 4.33. Post RT it slightlydecreased to 
66 ± 4.975, while post chemotherapyit further declined to 62.7 ± 
2.92.During follow up mean LVEF further decreased to 61.89 ± 2.934. 
In Group 4 baseline mean LVEF was 67.25 ± 4.33, which decreased 
after chemotherapy to 64.75 ± 2.062. During follow up it further 
decreased to 63.25 ± 2.363.  LVEF was also measured by MUGA/ ERV. 
In Group 1 mean LVEF at baseline was 58.14 ±2.997. After 
chemotherapy it decreased to 56.15 ± 3.144. After RT it increased to 
56.21 ± 3.81 and during follow up mean LVEF decreased to 55.21 ± 
2.913. In Group 2 mean LVEF at baseline was 59.11 ± 1.41. Post RT 
decreased to 58.67 ±2.872 and post chemotherapy it decreased to 
54.44 ± 1.81. During follow up it increased to 55.22 ± 1.787. In Group 
4 mean LVEF at baseline was 60 ± 1.63, which decreased to 58.75 ± 
1.89 after chemotherapy. During follow up it further decreased to 
56.25 ± 2.63. 
Conclusions: Our prospective study shows that a significant number of 
patients can develop a transient depression in ventricular function 
after chemotherapy and radiotherapy. ECG changes in our study were 
not specific. T wave inversion was the most common abnormality, 
suggestive of ventricular repolarisation abnormality. Decrease in LVEF 
was seen in our patients both by conventional ECHO and MUGA/ ERV 
scan during different phases of treatment. These changes indicate 
that doxorubicin based chemotherapy and radiotherapy produces 
acute abnormality in left ventricular function. Whether these results 
are predictive of the development of chronic cardiac toxicity can only 
be answered by serially investigating these patients for a longer 
duration. 
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Purpose/Objective: Linear accelerator delivered partial breast 
radiotherapy has a number of advantages over other technologies. 
These include: No new clinical skills, improved efficiency and 
economics, non invasive (vs. brachy), performed with known histology 
(vs. IORT), and ability to deliver accurate and uniform dosimetry. On 
the other hand, uncertainties in target localisation with external 
beam RT has resulted in large PTV expansion margins and increased 
dose to the surrounding normal tissue. This work determines the 
utility of a novel device that allows for accurate localisation and 
patient positioning, facilitating reduced treatment volumes for either 
APBI or breast boost following whole breast RT. 
Materials and Methods: A novel implantable device (BioZorb™ Tissue 
Marker) constructed of standard surgical materials (bio-absorbable 
polymer and Ti clips) has been developed. The polymer is formed into 
a semi-rigid spiral and shaped into a sphere or ellipsoid, with six clips 
strategically placed for visualisation and orientation. A range of sizes 
is available to match the lumpectomy cavity. The implant is placed 
into the cavity at the time of surgery. Several weeks post surgery, 
treatment planning CT (including respiratory gating) is performed. The 
envelope of the implant abutting the margin of the tissue cavity plus 
1cm defines the CTV with an additional 0.5cm expansion for the PTV. 
The treatment is delivered using either 3D conformal or VMAT. Patient 
setup is facilitated with CBCT and a post treatment scan to reveal 
residual error. 
Results: To date 3 patients have been treated using APBI with the 
implant. The average PTV was 84cc compared to 378cc worst case 
using all hyperdense tissue surrounding the cavity, and 788cc for the 
whole breast. The extent of respiratory motion ranged from 0.7 to 
2mm and mean residual error for all measured treatment fractions 
was 1mm (SD 2.3mm). Using a VMAT technique provided further 
enhancement to APBI reducing the non imaging component of 
treatment to 112sec with no floor rotations required and a 36% 
reduction in MU over a non coplanar 3D conformal method. 
 
Conclusions: This novel implantable device provides for greater 
certainty of target definition and assessment of respiratory motion 
when defining the PTV, facilitating the use of IGRT for partial breast 
treatment. Efficient image guided setup further allows for a reduction 
in margin. Post treatment imaging validates the use of a 0.5cm PTV 
expansion. Using this device in the breast parallels the use of other 
fiducially guided treatment sites such as the prostate. When 
positioning the patient, use of the implant serves as a significant 
improvement compared to highly uncertain target surrogates such as 
skin markers or random clips. The device is also able to provide 
certainty of target location in breast boost treatment where there is 
usually limited evidence of the location of the primary site at the 
time of boost.  
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Purpose/Objective: The assessment of the procedure safety in 
Intraoperative Radiotherapy (IORT) with mobile machines analyzes the 
risk of using the dedicated equipments and the misunderstandings in 
work flows. This procedures optimization should led to a prospective 
analysis and errors management that helps to identify potential 
failure modes and severity of the clinical consequences on patients. 
Aim of this experience is to review the Intraoperative Radiation 
Therapy process with the mobile linear accelerator Novac7, applying 
the Failure Mode and Effects Analysis (FMEA) to improve patients 
safety.  
Materials and Methods: The FMEA analysis provides a systematic 
method for finding vulnerabilities in a process before they result in an 
error. Three steps were identified: 1) process study with involved 
phases and activities; 2) hazard analysis with identification of possible 
failure modes and their effects, calculating for each failure mode the 
risk probability number(RPN) by the product of three scores (severity, 
frequency and detectability of that failure, each on a scale of 1 to 
10); 3) planning additional safety measures scored for effectiveness (1 
to 10) and feasibility (1 to 10). The RPN scores can span a range of 1 
to 1000; decisions are made based on the RPN values. The RPN value 
less than 125 was considered of little concern of risk. 
Results: The FMEA analysis was tested on breast cancer patients 
treated with IORT in our centre from 2005 on. The procedure was 
examined in a multidisciplinary view. With regard to a medical 
perspective the main reported clinical risks were in patient’s 
identification, indication to treat and timing with other therapies. In 
our experience the use of standardized protocols and a good informed 
consent modality, shared between surgeon and radiotherapist, was 
able to reduce the risk and was a simple way to implement the 
results. The dose prescription, consisting of the volume to be treated, 
the used technique, the dose, energy and organs at risk (OAR) 
identification were checked with a written list and a double control, 
shared between physicist and radiotherapist, was performed. 
Technically each point of IORT was described and a report of the 
procedure was always inserted in the medical chart and into the 
software dedicated to Radiotherapy Department. Physical critical 
failure modes were identified as incorrect data entry at treatment 
console and underestimation of CTV extension, resulting in wrong dose 
distribution and CTV under-dosage. Several safety solutions were 
proposed, including in vivo dosimetry. 
Conclusions: FMEA is a widely-used tool for improving safety and can 
be easily adapted for IORT optimization. New risk management 
strategies can provide highly qualified procedures for avoiding the 
increase in acute and late toxicity and in the reduction of tumor 
control. The impact of this tool is under study.  
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Purpose/Objective: There is no consensus on boost target volume 
delineation in conserved breast in locally advanced breast cancer 
(LABC) after neoadjuvant chemotherapy (NACT). Inclusion of 
prechemotherapy target volume has the disadvantage of large 
volumes which will have a detrimental effect on cosmesis. Inclusion of 
postchemotherapy target volume has the advantage of smaller target 
volume but there could be a higher risk of recurrence.We therefore 
did a retrospective analysis of LABC patients who underwent breast 
conservation (BCS) after NACT to assess whether post NACT target 
volumes are adequate for achieving local control. 
Materials and Methods: Patients of LABC who underwent BCS and 
radiotherapy after NACT, registered between 2007-2011 were the 
subject of our analysis. After BCS,patients received whole breast and 
supraclavicular radiotherapy (50Gy/25 fractions/5wk or 42.4Gy/16# / 
3 wk) which was followed by boost (10-16Gy/5-8#/1-1.5wk). After 
evaluating patterns of recurrence in these patients, the information 
on lumpectomy specimen size, method of estimating tumour boost 
field size (whether based on visible scar, tumour cavity on CT scan, 
prechemotherapy tumour size or postchemotherapy tumour size) was 
sought to gain an insight on whether these had an impact on the local 
recurrence. 
Results: 43 patients were the subject of this analysis. The median age 
was 47 years,42% were premenopausal and 58% were postmenopausal. 
Histopathological subtypes were luminal A (23%), luminal B (23%), Her- 
2 type(14%) and basal type (40%). (47.7%)patients had stage II 
disease,12 (27.2%) had III A and 10 (22.7%) had IIIB disease at 
presentation. After NACT 33.3% patients acheived CR (complete 
response), 54.8% PR (partial response) and 11.8% had SD (stable 
disease). The surgical margins around tumour in lumpectomy 
specimens were based on pre-chemotherapy tumour size in all 
patients. Radiotherapy planning scan revealed tumour cavity in 33 
patients and clips in 19 patients. Boost target delineation was based 
on visible scar: 4 patients ( 9.7%), tumour cavity: 5 patients (12.1%), 
prechemotherapy target volume : 5 patients (12.1%) and post 
chemotherapy target volume:27 patients (65%). 2 patients did not 
receive a boost. At a median followup of 27.2 months (4-71 
months),no patient had ipsilateral breast tumour recurrence (IBTR), 
one patient had ipsilateral axillary node recurrence and four patients 
had distant metastases. 
Conclusions: Postchemotherapy target volume seems to be safe as 
boost volume delineation for radiotherapy in patients with LABC who 
undergo BCS after NACT. 
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Purpose/Objective: To assess the comparative effectiveness of 
traditional (normal-dose) and reductional (low-dose) variants of 
postmastectomy chest-wall irradiation with the criteria of local 
control, overall and relapse-free survival rates, frequency of 
postradiation cardiac complications. 
Materials and Methods: Two groups of patients with breast cancer IIB 
– IIIB stages were studied: the 1st group – variant of normal-dose (50 
Gy to chest wall in 25fractions) radiation therapy with/without 
chemotherapy (129 patients), the 2nd group – variant of low-dose (40 
Gy to chest wall in 20 fractions) radiation therapy with/without 
chemotherapy (82 patients). In all cases radiation therapy followed 
Madden mastectomy. Dose to regional areas (46-50 Gy according to 
the number of metastatic lymphatic nodes) as well as neoadjuvant 
and adjuvant chemotherapy regimes was similar in both groups. The 
median follow-up was 111 and 95 months for the 1st and 2nd group 
respectively. 
Results: Frequency of 5-year actuarial local-regional progression in 
case of normal-dose and low-dose variants was estimated as 6,2±2,1% 
and 3,7±2,1% respectively (p=0,4). Metastases developed in 34,6±4,2% 
and 19,5±4,4% of patients in the 1st and 2nd group (p<0,05). 5-year 
relapse-free survival was53,5±5,4% and 71,5.±6,4% and overall survival 
- 65,3±5,6% and 72,2±6,3% for the 1 and 2 group respectively (?=0,08). 
Late failure in ECG in patients with left-side chest-wall irradiation 
were detected in 55±11,1% in the low-dose group comparing to 
75±9,7% in the normal-dose group (?<0,05). 
Conclusions: There are no statistically significant differences in local 
control, overall and relapse-free survival rates of traditional normal-
dose and low-dose variants of postmastectomy chest-wall irradiation. 
This method of dose-reduced postmastectomy chest-wall irradiation in 
compliance with modern systemic treatment allows to decline risk of 
cardiotoxicity with the maintenance of the treatment effectiveness 
achieved by using traditional method. 
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Purpose/Objective: The aim of our report – to compare the results of 
different regimes of whole-breast irradiation (accelerated 
hypofractionated, dynamic hypofractionated and, standard radiation 
treatment) following breast-conserving surgery for breast cancer I-IIA 
stages. 
Materials and Methods: From 2000 till 2005 yy 333 patients aged R54 
years received whole-breast irradiation following breast-conserving 
surgery (lumpectomy + axillary and internal lymphatic dissection). The 
most commonly seen invasive ductal carcinoma (55%), the rare - 
Invasive lobular carcinoma (27%), Invasive ductal cancer with 
extensive in situ component (3%) and special forms (15%). Metastasis 
in ipsilateral axillary lymph nodes fixed in 17,4% cases. All patients 
received whole-breast irradiation with different regimens RT: 1 group 
- accelerated hypofractionated (3Gy per fraction over 2,5 weeks, total 
dose of 39Gy, N=112), 2 group – dynamic hypofractionated (5Gy per 
fraction - 2, then 2,5 per fraction - 15, over 3,5 weeks, total dose of 
47,5Gy, N=130) and 3 group - standard radiation treatment (2 Gy per 
fraction over 5 weeks, total dose of 45–50 Gy, N=91). We used three-
dimensional CT-based treatment planning, two traditional tangent 
radiotherapy fields 6-18 MV, changing the gantry angle, collimator 
angle, blocks to result in coverage of the breast while excluding the 
heart from the treatment fields and minimized dose to the lung. Local 
relapse: 0% (1 group), 0,9% (2 and 3 groups) at 5 years. Five-year 
